FPXE Fact Sheet: First Trust IPOX Europe Equity Opportunities ETF
Share
$30.45
close, Nov 18, 2026
Over the year to Nov 18, 2026, FPXE returned +4.0% in total and charged 0.70% a year.
- 1-year total return
- +4.0%
- to Nov 18, 2026
- Expense ratio
- 0.70%
- a year
- Net assets
- $4.6m
- on Nov 17, 2026
- Net flow, last 5 trading days
- $0
- daily basis to Nov 17, 2026
Growth of $10,000, 1 year
FPXE $10,401 +4.0% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month−1.3%
3 months−9.6%
Year to date−1.8%
1 year+4.0%
3 years+51.9%
5 years+1.4%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
Roche Holding AG8.08%
Swedish Orphan Biovitrum AB6.91%
Ascendis Pharma A/S6.68%
BAWAG Group AG6.50%
Nordnet AB (publ)6.11%
Lottomatica Group SpA5.17%
Technoprobe SpA4.20%
Arm Holdings Plc3.24%
Andritz AG3.07%
Sandoz Group AG2.88%
FPXE top ten by weight, 52.8% of the fund, of its 101 equity positions, from the holdings published by its issuer for Nov 17, 2026.
Facts
Equity fund · Tracks the IPOX -100 Europe Index · First traded Oct 5, 2018 · Benchmark Its own holdings, as of Nov 17, 2026